Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John A Donovan

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Gastrointestinal Endoscopy Clinics of North America|April 2, 2013
Biliary manifestations of systemic diseasesZaree Babakhanian, John A Donovan
Hepatology Communications|February 7, 2018
Prediction of histologic alcoholic hepatitis based on clinical presentation limits the need for liver biopsyNitzan C Roth, Behnam Saberi, Jared Macklin, et al.
Eclinicalmedicine|October 21, 2022
A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitisJohn A Tayek, Andrew A Stolz, Danh V Nguyen, et al.
Gastroenterology|November 15, 2006
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis CHerbert L Bonkovsky, Deepa Naishadham, Richard W Lambrecht, et al.
Gastrointestinal Endoscopy|December 5, 2006
The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosisArun J Sanyal, Robert J Fontana, Adrian M Di Bisceglie, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Gastrointestinal Endoscopy Clinics of North America|April 2, 2013
Biliary manifestations of systemic diseasesZaree Babakhanian, John A Donovan
Hepatology Communications|February 7, 2018
Prediction of histologic alcoholic hepatitis based on clinical presentation limits the need for liver biopsyNitzan C Roth, Behnam Saberi, Jared Macklin, et al.
Eclinicalmedicine|October 21, 2022
A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitisJohn A Tayek, Andrew A Stolz, Danh V Nguyen, et al.
Gastroenterology|November 15, 2006
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis CHerbert L Bonkovsky, Deepa Naishadham, Richard W Lambrecht, et al.
Gastrointestinal Endoscopy|December 5, 2006
The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosisArun J Sanyal, Robert J Fontana, Adrian M Di Bisceglie, et al.
Pageof 1